JP2024094370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024094370A5 JP2024094370A5 JP2024066342A JP2024066342A JP2024094370A5 JP 2024094370 A5 JP2024094370 A5 JP 2024094370A5 JP 2024066342 A JP2024066342 A JP 2024066342A JP 2024066342 A JP2024066342 A JP 2024066342A JP 2024094370 A5 JP2024094370 A5 JP 2024094370A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- blocking antibody
- administered
- tnfα
- chemokine receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 32
- 230000000903 blocking effect Effects 0.000 claims 16
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 8
- 108010089833 chemokine receptor D6 Proteins 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 102000006495 integrins Human genes 0.000 claims 8
- 108010044426 integrins Proteins 0.000 claims 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 230000002195 synergetic effect Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060454P | 2014-10-06 | 2014-10-06 | |
| US62/060,454 | 2014-10-06 | ||
| JP2020082164A JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2022016197A JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022016197A Division JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024094370A JP2024094370A (ja) | 2024-07-09 |
| JP2024094370A5 true JP2024094370A5 (enExample) | 2025-03-19 |
Family
ID=55632011
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518197A Active JP6954834B2 (ja) | 2014-10-06 | 2015-10-05 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2020082164A Active JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2022016197A Pending JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2024066342A Pending JP2024094370A (ja) | 2014-10-06 | 2024-04-16 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518197A Active JP6954834B2 (ja) | 2014-10-06 | 2015-10-05 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2020082164A Active JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2022016197A Pending JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10532051B2 (enExample) |
| EP (2) | EP4268820A3 (enExample) |
| JP (4) | JP6954834B2 (enExample) |
| KR (3) | KR102642382B1 (enExample) |
| CN (1) | CN107001467A (enExample) |
| AU (1) | AU2015328396B2 (enExample) |
| CA (2) | CA3224013A1 (enExample) |
| ES (1) | ES2971041T3 (enExample) |
| IL (2) | IL251136B (enExample) |
| MA (1) | MA40592A (enExample) |
| MX (2) | MX2017004344A (enExample) |
| NZ (1) | NZ768528A (enExample) |
| RU (1) | RU2713653C2 (enExample) |
| SG (1) | SG11201702793XA (enExample) |
| WO (1) | WO2016057424A1 (enExample) |
| ZA (1) | ZA201701852B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104520288B (zh) * | 2012-02-29 | 2017-05-17 | 坎莫森特里克斯公司 | 作为ccr9拮抗剂的吡唑‑1‑基苯磺酰胺 |
| WO2016057424A1 (en) * | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
| JP7129912B2 (ja) * | 2016-12-07 | 2022-09-02 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
| US20210154292A1 (en) * | 2019-11-21 | 2021-05-27 | Chemocentryx, Inc. | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| JP7787823B2 (ja) * | 2020-03-31 | 2025-12-17 | ケモセントリックス， インコーポレイテッド | Ｃｃｒ９阻害剤及び抗ｉｌ－２３遮断抗体を使用する炎症性腸疾患を治療するための組成物及び方法 |
| CN114314701B (zh) * | 2021-11-30 | 2023-10-20 | 昆明贵研药业有限公司 | 一种三氯氨铂酸钾的制备方法及其在制备顺式-氨-水-铂配合物中的应用 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2025177214A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| US6451399B1 (en) | 2001-02-05 | 2002-09-17 | Daniel G. Boyce | Display mat |
| EP2402310A1 (en) * | 2002-05-24 | 2012-01-04 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| EP2256116A3 (en) | 2002-11-18 | 2011-11-16 | ChemoCentryx, Inc. | Aryl sulfonamides |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| TW200510311A (en) | 2002-12-23 | 2005-03-16 | Millennium Pharm Inc | CCr8 inhibitors |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| CA2566387A1 (en) | 2004-05-12 | 2005-12-01 | Chemocentryx, Inc. | Aryl sulfonamides as chemokine receptor ccr9 antagonists |
| SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US20120283411A9 (en) * | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| AU2007272972B2 (en) | 2006-07-14 | 2011-12-01 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| ATE483685T1 (de) | 2007-02-06 | 2010-10-15 | Novartis Ag | 1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| KR101346530B1 (ko) | 2009-03-20 | 2013-12-31 | 암젠 인크 | 알파-4-베타-7 이종이량체 특이적 길항제 항체 |
| US10040855B2 (en) | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2013016174A1 (en) | 2011-07-22 | 2013-01-31 | Chemocentryx, Inc. | A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide |
| WO2013016155A1 (en) | 2011-07-22 | 2013-01-31 | Glaxo Group Limited | Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| JP6166721B2 (ja) | 2011-07-22 | 2017-07-19 | ケモセントリックス， インコーポレイテッド | ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の多形 |
| CN104520288B (zh) * | 2012-02-29 | 2017-05-17 | 坎莫森特里克斯公司 | 作为ccr9拮抗剂的吡唑‑1‑基苯磺酰胺 |
| WO2016057424A1 (en) * | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
-
2015
- 2015-10-05 WO PCT/US2015/054077 patent/WO2016057424A1/en not_active Ceased
- 2015-10-05 ES ES15848916T patent/ES2971041T3/es active Active
- 2015-10-05 KR KR1020237009744A patent/KR102642382B1/ko active Active
- 2015-10-05 EP EP23197483.3A patent/EP4268820A3/en active Pending
- 2015-10-05 RU RU2017115809A patent/RU2713653C2/ru active
- 2015-10-05 CA CA3224013A patent/CA3224013A1/en active Pending
- 2015-10-05 IL IL251136A patent/IL251136B/en unknown
- 2015-10-05 NZ NZ768528A patent/NZ768528A/en unknown
- 2015-10-05 US US14/875,506 patent/US10532051B2/en active Active
- 2015-10-05 SG SG11201702793XA patent/SG11201702793XA/en unknown
- 2015-10-05 IL IL292655A patent/IL292655B2/en unknown
- 2015-10-05 EP EP15848916.1A patent/EP3204424B1/en active Active
- 2015-10-05 MX MX2017004344A patent/MX2017004344A/es unknown
- 2015-10-05 CN CN201580054158.XA patent/CN107001467A/zh active Pending
- 2015-10-05 KR KR1020247006273A patent/KR20240033093A/ko not_active Ceased
- 2015-10-05 AU AU2015328396A patent/AU2015328396B2/en active Active
- 2015-10-05 MA MA040592A patent/MA40592A/fr unknown
- 2015-10-05 CA CA2960876A patent/CA2960876C/en active Active
- 2015-10-05 KR KR1020177012272A patent/KR102514565B1/ko active Active
- 2015-10-05 JP JP2017518197A patent/JP6954834B2/ja active Active
-
2017
- 2017-03-15 ZA ZA2017/01852A patent/ZA201701852B/en unknown
- 2017-04-03 MX MX2022008951A patent/MX2022008951A/es unknown
-
2019
- 2019-12-09 US US16/708,167 patent/US11020394B2/en active Active
-
2020
- 2020-05-07 JP JP2020082164A patent/JP7025781B2/ja active Active
- 2020-05-14 US US15/929,647 patent/US11045469B2/en active Active
-
2021
- 2021-05-24 US US17/328,293 patent/US20210322410A1/en not_active Abandoned
-
2022
- 2022-02-04 JP JP2022016197A patent/JP2022051829A/ja active Pending
-
2024
- 2024-04-16 JP JP2024066342A patent/JP2024094370A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024094370A5 (enExample) | ||
| Clark | How TNF was recognized as a key mechanism of disease | |
| Clark | The advent of the cytokine storm. | |
| Shapira et al. | Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion | |
| Fleischmann et al. | Safety of extended treatment with anakinra in patients with rheumatoid arthritis | |
| Fekade et al. | Prevention of Jarisch–Herxheimer reactions by treatment with antibodies against tumor necrosis factor α | |
| Dammacco et al. | Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis | |
| Granger et al. | Acute pancreatitis: models, markers, and mediators | |
| Nestorov | Clinical pharmacokinetics of tumor necrosis factor antagonists. | |
| JP2017530163A5 (enExample) | ||
| KR101780666B1 (ko) | Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도 | |
| JP5039550B2 (ja) | 大腸炎の治療のための組成物及び方法 | |
| Andrejko et al. | Intrahepatic STAT-3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat | |
| Sheron et al. | IL-8 as a circulating cytokine: induction by recombinant tumour necrosis factor-alpha | |
| Daliento et al. | Successful treatment of enterovirus-induced myocarditis with interferon-α | |
| US20200268751A1 (en) | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies | |
| CN112807434B (zh) | Perk抑制剂在制备肝癌药物的增效剂中的应用 | |
| HK1044887A1 (en) | Use of tumor necrosis factor alpha (tnf-alpha) and vascular endothelial growth factor (vegf) for the manufacture of a therapeutic composition | |
| D'Haens | Anti-TNF therapy for Crohn's disease | |
| Tsimberidou et al. | TNF-α targeted therapeutic approaches in patients with hematologic malignancies | |
| Van der Poll et al. | Effect of postponed treatment with an anti‐tumour necrosis factor (TNF) F (ab') 2 fragment on endotoxin‐induced cytokine and neutrophil responses in chimpanzees | |
| JP2025163244A (ja) | ベンズイミダゾール誘導体化合物を含む医薬組成物 | |
| RU2024107237A (ru) | Комбинированная терапия ингибиторами с-с хемокинового рецептора 9 (ccr9) и антителами, блокирующими альфа4бета7-интегрин | |
| Jacobi et al. | Treatment of inflammatory dermatoses by tumour necrosis factor antagonists | |
| US6143752A (en) | Method for preventing or arresting liver damage in humans |